Publicaciones

El número de publicaciones en revistas científicas desde el año 2007 ha sido de 43, con un factor de impacto de 185,831.

Para calcular el factor de impacto se ha utilizado el Journal Citation Reports (JCR) del año de publicación del artículo (no se han tenido en cuenta los Meeting Abstract).

43Total Publicaciones

180Factor Impacto

6Publicaciones en D1

14Publicaciones en Q1

2024

Hontecillas-Prieto L, García-Domínguez DJ, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Sánchez-León ML, Silva-Romeiro S, Flores-Campos R, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, Provencio-Pulla M, Sánchez-Beato M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Rueda-Domínguez A, Sánchez-Margalet V, de la Cruz-Merino L. CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma. Front Immunol. 2024 Feb 26;15:1293931. doi: 10.3389/fimmu.2024.1293931. PMID: 38469299; PMCID: PMC10926187. FIA: 5,9. Q1.
Martínez-Banaclocha N, Martínez-Madueño F, Caballé B, Badia J, Blanes M, Bujanda DA, Calvo V, Gómez Codina J, Blanco CQ, Espinosa P, Lavernia J, Arroyo FRG, Risueño MG, Llorca C, Cumeras R, Provencio Pulla M, Gumà J. A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL). Cancers (Basel). 2024 Mar 3;16(5):1034. doi: 10.3390/cancers16051034. PMID: 38473391; PMCID: PMC10931196. FIA: 4,4. Q1.
Fernández-Miranda I, Pedrosa L, González-Rincón J, Espinet B, de la Cruz Vicente F, Climent F, Gómez S, Royuela A, Camacho FI, Martín-Acosta P, Yanguas-Casás N, Domínguez M, Méndez M, Colomo L, Salar A, Horcajo B, Navarro M, García-Cosío M, Piris-Villaespesa M, Llanos M, García JF, Sequero S, Mercadal S, García-Hernández S, Navarro B, Mollejo M, Provencio M, Sánchez-Beato M. Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma. Mod Pathol. 2024 May 17;37(7):100516. doi: 10.1016/j.modpat.2024.100516. Epub ahead of print. PMID: 38763418. FIA: 5.5. D1.

2023

Sánchez-Beato M, Méndez M, Guirado M, Pedrosa L, Sequero S, Yanguas-Casás N, de la Cruz-Merino L, Gálvez L, Llanos M, García JF, Provencio M. A genetic profiling guideline to support diagnosis and clinical management of lymphomas. Clin Transl Oncol. 2024 May;26(5):1043-1062. doi: 1007/s12094-023-03307-1. Epub 2023 Sep 6. PMID: 37672206; PMCID: PMC11026206. FIA: 2,8. Q2
Gumà J, Palazón-Carrión N, Rueda-Domínguez A, Sequero S, Calvo V, García-Arroyo R, Gómez-Codina J, Llanos M, Martínez-Banaclocha N, Provencio M. SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022). Clin Transl Oncol. 2023 Sep;25(9):2749-2758. doi: 1007/s12094-023-03206-5. Epub 2023 Jun 8. PMID: 37289353; PMCID: PMC10425474. FIA: 2,8. Q2
Fernández-Miranda I, Pedrosa L, Llanos M, Franco FF, Gómez S, Martín-Acosta P, García-Arroyo FR, Gumá J, Horcajo B, Ballesteros AK, Gálvez L, Martínez N, Marín M, Sequero S, Navarro M, Yanguas-Casás N, Calvo V, Rueda-Domínguez A, Provencio M, Sánchez-Beato M. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study. Clin Cancer Res. 2023 Jan 4;29(1):209-220. doi: 1158/1078-0432.CCR-22-1654. PMID: 36269794; PMCID: PMC9811164. FIA: 10,4. D1

2022

Fernández-Miranda I, Pedrosa L, Llanos M, Franco FF, Gómez S, Martín-Acosta P, García-Arroyo FR, Gumá J, Horcajo B, Ballesteros AK, Gálvez L, Martínez N, Marín M, Sequero S, Navarro M, Yanguas-Casás N, Calvo V, Rueda-Domínguez A, Provencio M, Sánchez-Beato M..
Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study.
Clin Cancer Res. 2022. 29(1):209-220. 10.1158/1078-0432.CCR-22-1654. FIA: 11,5. D1
Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, García-Domínguez DJ, Hontecillas-Prieto L, Espejo-García P, Fernández-Román I, Provencio-Pulla M, Sánchez-Beato M, Navarro M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Sánchez-Margalet V, Rueda-Domínguez A, de la Cruz-Merino L..
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Clin Cancer Res. 2022. 28(17):3658-3668. 10.1158/1078-0432.CCR-22-0588. FIA: 11,5. D1

2021

Franco F, Guirado M, Martínez-Banaclocha N, Gumà J, Lavernia J, Gómez-Codina J, Rodriguez-Abreu D, Martínez F, Barrajón E, Méndez M, Calvo V, Provencio M..
Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel).
Curr Oncol. 2021. 28(2): 1249-1255. 10.3390/curroncol28020118. FIA: 3,677. Q3
Núñez-García B, Rodríguez-Pertierra M, Sequero S, Carvajal LG, Ruano-Ravina A, Aguiar D, Gumá J, Blanco CQ, García Arroyo FR, Garitaonaindia Y, Provencio Z, Calvo V, González-San Segundo C, Provencio M..
Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group.
Hematol Oncol. 2021. 39(4): 506-512. 10.1002/hon.2835. FIA: 5,271. Q2
Jiménez-Cortegana C, Sánchez-Martínez PM, Palazón-Carrión N, Nogales-Fernández E, Henao-Carrasco F, Martín García-Sancho A, Rueda A, Provencio M, de la Cruz-Merino L, Sánchez-Margalet V..
Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial.
Cancers (Basel). 2021. 13(18). 10.3390/cancers13184622. FIA: 6,639. Q1
Jiménez-Cortegana C, Palazón-Carrión N, Martin Garcia-Sancho A, Nogales-Fernandez E, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Rueda Dominguez A, Casanova-Espinosa M, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Labrador J, Salar-Silvestre A, Rodriguez-Abreu D, Galvez-Carvajal L, Provencio M, Sánchez-Beato M, Guirado-Risueño M, Espejo-García P, Lejeune M, Álvaro T, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA)..
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
J Immunother Cancer. 2021. 9(6). 10.1136/jitc-2020-002323. FIA: 13,751. Q1
Pedrosa L, Fernández-Miranda I, Pérez-Callejo D, Quero C, Rodríguez M, Martín-Acosta P, Gómez S, González-Rincón J, Santos A, Tarin C, García JF, García-Arroyo FR, Rueda A, Camacho FI, García-Cosío M, Heredero A, Llanos M, Mollejo M, Piris-Villaespesa M, Gómez-Codina J, Yanguas-Casás N, Sánchez A, Piris MA, Provencio M, Sánchez-Beato M..
Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
Sci Rep. 2021. 11(1). 10.1038/s41598-020-80376-0. FIA: 4,38. Q1
Rodriguez-Pinilla SM, Domingo-Domenech E, Climent F, Sanchez J, Perez Seoane C, Lopez Jimenez J, Garcia-Cosio M, Caballero D, Blanco Muñez OJ, Carpio C, Castellvi J, Martinez Pozo A, Gonzalez Farre B, Bendaña A, Aliste C, Gonzalez AJ, Gonzalez de Villambrosia S, Piris MA, Gomez Codina J, Mayordomo-Aranda E, Navarro B, Bellas C, Rodriguez G, Borrero JJ, Ruiz-Zorrilla A, Grande M, Montoto C, Cordoba R..
Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
Br J Haematol. 2021. 192(1): 82-99. 10.1111/bjh.16741. FIA: 6,998. Q1

2020

Núñez-García B, Rodríguez-Pertierra M, Sequero S, Carvajal LG, Ruano-Ravina A, Aguiar D, Gumá J, Blanco CQ, García Arroyo FR, Garitaonaindia Y, Provencio Z, Calvo V, González-San Segundo C, Provencio M.. Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group. Hematol Oncol.2020. 39(4): 506-512. 10.1002/hon.2835. FIA: 5,271. Q2

Gonzalez-Barca, E; Capote, FJ; Gomez-Codina, J; Panizo, C; Salar, A; Sancho, JM; Lopez, A; Briones, J; Munoz, A; Encuentra, M; Mercadal, S; Domingo-Domenech, E; de Sevilla, AF. Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. ANNALS OF HEMATOLOGY. (): -. 10.1007/s00277-020-04056-9. FIA: 3,673. Q2

2019

Rueda, A; Calvo, V; Casanova, M; Rodriguez-Abreu, D; Aguiar, D; Llanos, M; Alvarez, R; Martinez-Banaclocha, N; Alfaro, J; Quero, C; Blasco, A; Merino, LDLC; Herrero, J; Garcia-Arroyo, FR; Provencio, M.
Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
LEUKEMIA & LYMPHOMA. 2019. 60(6): 1579-1576. 10.1080/10428194.2018.1542147. FIA: 2,969. Q2
Mendez, M; Torrente, M; Sanchez-Beato, M; Gonzalez-Rincon, J; Royuela, A; Gomez-Codina, J; de la Cruz-Merino, L; Rueda, A; Llanos, M; Quero, C; Rodriguez-Abreu, D; Guma, J; Monsalvo, S; Sabin, P; Provencio, M.
Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.
HEMATOLOGICAL ONCOLOGY. 2019. 37(2): 150-143. 10.1002/hon.2601. FIA: 2,832. Q2
Gonzalez-Rincon, J; Mendez, M; Gomez, S; Garcia, JF; Martin, P; Bellas, C; Pedrosa, L; Rodriguez-Pinilla, SM; Camacho, FI; Quero, C; Perez-Callejo, D; Rueda, A; Llanos, M; Gomez-Codina, J; Piris, MA; Montes-Moreno, S; Barcena, C; Rodriguez-Abreu, D; Menarguez, J; De la Cruz-Merino, L; Monsalvo, S; Parejo, C; Royuela, A; Kwee, I; Cascione, L; Arribas, A; Bertoni, F; Mollejo, M; Provencio, M; Sanchez-Beato, M.
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.
PLOS ONE. 2019. 14(2): -. 10.1371/journal.pone.0212813. FIA: 2,74. Q2
Provencio, M; Franco, F; Gomez-Codina, J; Blanco, CQ; Llanos, M; Garcia-Arroyo, F; de la Cruz, L; Guma, J; Delgado, JR; Alvarez, R; Chacon, JI; Royuela, A; Rueda, A.
Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years.
LEUKEMIA & LYMPHOMA. 2019. 60(3): 859-856. 10.1080/10428194.2018.1509322. FIA: 2,969. Q2

2017

Franco, F; Gonzalez-Rincon, J; Lavernia, J; Garcia, JF; Martin, P; Bellas, C; Piris, MA; Pedrosa, L; Miramon, J; Gomez-Codina, J; Rodriguez-Abreu, D; Machado, I; Illueca, C; Alfaro, J; Provencio, M; Sanchez-Beato, M.
Mutational profile of primary breast diffuse large B-cell lymphoma.
ONCOTARGET. 2017. 8(61): 102897-102888. 10.18632/oncotarget.21986. FIA: 0. Q0
Provencio, M; Royuela, A; Torrente, M; Pollan, M; Gomez-Codina, J; Sabin, P; Llanos, M; Guma, J; Quero, C; Blasco, A; Aguiar, D; Garcia-Arroyo, FR; Lavernia, J; Martinez, N; Morales, M; Saenz-Cusi, A; Rodriguez, D; Calvo, V; de la Cruz-Merino, L; de la Cruz, MA; Rueda, A.
Prognostic Value of Event-Free Survival at 12 and 24 Months and Long-Term Mortality for Non-Hodgkin Follicular Lymphoma Patients: A Study Report From the Spanish Lymphoma Oncology Group.
CANCER. 2017. 123(19): 3716-3709. 10.1002/cncr.30795. FIA: 6,537. Q1
Provencio, M; Rodriguez, M; Cantos, B; Sabin, P; Quero, C; Garcia-Arroyo, FR; Rueda, A; Maximiano, C; Rodriguez-Abreu, D; Sanchez, A; Silva, J; Garcia, V.
mRNA in exosomas as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish lymphoma oncology group.
ONCOTARGET. 2017. 8(31): 50957-50949. 10.18632/oncotarget.16435. FIA: 0. Q0
Provencio, M; Sabin, P; Gomez-Codina, J; Torrente, M; Calvo, V; Llanos, M; Guma, J; Quero, C; Blasco, A; Cruz, MA; Aguiar, D; Garcia-Arroyo, F; Lavernia, J; Martinez, N; Morales, M; Saez-Cusi, A; Rodriguez, D; de la Cruz, L; Sanchez, JJ; Rueda, A.
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.
PLOS ONE. 2017. 12(5): -. 10.1371/journal.pone.0177204. FIA: 2,766. Q1
Perez, FF; Lavernia, J; Aguiar-Bujanda, D; Miramon, J; Guma, J; Alvarez, R; Gomez-Codina, J; Arroyo, FG; Llanos, M; Marin, M; Alfaro, J; Quero, C; Delgado, M; Nogales, E; Menarguez, F; Martinez, N; Torrente, M; Royuela, A; Abreu, D; Provencio, M.
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2017. 17(3): 191-186. 10.1016/j.clml.2016.09.004. FIA: 2,308. Q3
Mendez, M; Torrente, M; Provencio, M.
Follicular lymphomas and their transformation: Past and current research.
EXPERT REVIEW OF HEMATOLOGY. 2017. 10(6): 524-515. 10.1080/17474086.2017.1326812. FIA: 1,937. Q3

2016

Calvo, V; Provencio, M; Codina, JG; Abreu, DR; Rueda, A.
Survival in young adults diagnosed with follicular lymphoma.
ANNALS OF ONCOLOGY. 27(4): 751-751. 10.1093/annonc/mdv627. FIA: 11,855. Q1

2015

Dominguez, AR; Lizaso, JA; Merino, LD; Padro, JGI; Blanco, CQ; Codina, JG; Munoz, ML; Banaclocha, NM; Abreu, DR; Pulla, MP.
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma.
CLINICAL & TRANSLATIONAL ONCOLOGY. 17(12): 1013-1005. 10.1007/s12094-015-1429-1. FIA: 2,075. Q3
Pulla, MP; Lizaso, JA; Merino, LD; Padro, JGI; Blanco, CQ; Codina, JG; Munoz, ML; Banaclocha, NM; Abreu, DR; Dominguez, AR.
SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma.
CLINICAL & TRANSLATIONAL ONCOLOGY. 2015. 17(12): 1019-1014. 10.1007/s12094-015-1437-1. FIA: 2,075. Q3
Rueda, A; Garcia-Sanz, R; Pastor, M; Salar, A; Labrador, J; Quero-Blanco, C; Casanova, M; Provencio, M.
A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma.
ACTA ONCOLOGICA. 2015. 54(6): 938-933. 10.3109/0284186X.2015.1007212. FIA: 3,73. Q2
Rueda, A; Olmos, D; Vicioso, L; Quero, C; Gallego, E; Pajares-Hachero, BI; Mendiola, M; Casanova, M; Alvarez, M; Provencio, M; Alba, E.
Role of vascular endothelial growth factor C in classical Hodgkin lymphoma.
LEUKEMIA & LYMPHOMA. 2015. 56(5): 1294-1286. 10.3109/10428194.2014.952227. FIA: 3,093. Q2

2014

Montes-Moreno, S; Batlle, A; de Villambrosa, SG; Sanchez-Espiridion, B; Cereceda, L; Gonzalez-Barca, E; Purroy, N; Pardal, E; Martin, A; Grande, C; Mazorra, F; Insunza, A; Quero, C; Aguiar, D; Cruz, MA; Rueda, A; Llanos, M; Codina, JG; Arroyo, FRG; Caballero, D; Conde, E; Lopez, A; Provencio, M; Piris, M.
Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis.
HAEMATOLOGICA. 2014. 99(8): E141-E138. 10.3324/haematol.2014.104976. FIA: 5,814. Q1
Rueda, A; Rifa, J; Quero, C; Gomez-Codina, J; Murias, A; Garcia-Arroyo, FR; Sabin, P; Llanos, M; Herrero, J; Lobo, F; Delgado, JR; Provencio, M.
High serum levels of vascular endothelial growth factor-C have a positive impact on outcome of patients with advanced diffuse large B cell lymphoma.
LEUKEMIA & LYMPHOMA. 2014. 55(6): 1416-1413. 10.3109/10428194.2013.836601. FIA: 2,891. Q2
Provencio, M; Mora, MAC; Gomez-Codina, J; Blanco, CQ; Llanos, M; Garcia-Arroyo, FR; de la Cruz, L; Padro, JG; Perez, JRD; Sanchez, A; Cabellos, RA; Rueda, A.
Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.
LEUKEMIA & LYMPHOMA. 2014. 55(1): 55-51. 10.3109/10428194.2013.790544. FIA: 7,153. Q2
Sánchez Ruiz AC, de la Cruz-Merino L, Provencio Pulla M.
Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma.
Ther Adv Hematol. 2014. 5(3):78-90. 10.1177/2040620714532282. FIA: 0. Q0

2012

Provencio, M; Sabin, P; Codina, JG; Rueda, A; Llanos, M; Guma, J; Blanco, CQ; Blasco, A; Delgado, JR; Cruz, MA; Aguiar, D; Garcia-Arroyo, FR; Herrero, J; Lavernia, J; Banaclocha, NM; Morales, M; Fuster, J; Cusi, AS; Lobo, F; Abreu, DR; de la Cruz, L; Anton, E; Jimenez, AR; Arizcun, A; Perez, X.
Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain?.
CLINICAL & TRANSLATIONAL ONCOLOGY. 2012. 52(): 14-1. 10.1007/s12094-012-0813-3. FIA: 1,276. Q4

2011

Lopez-Guillermo, A; Caballero, D; Canales, M; Provencio, M; Rueda, A; Salar, A.
Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma.
LEUKEMIA & LYMPHOMA. 2011. 12(11): 759-753. 10.3109/10428194.2011.629897. FIA: 2,58. Q2

2010

Blanco, CQ; Arroyo, RG; Pulla, MP; Dominguez, AR; Casado, DI.
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma.
CLINICAL & TRANSLATIONAL ONCOLOGY. 2010. 12(11): 769-765. 10.1007/s12094-010-0591-8. FIA: 1,254. Q4
Codina, JG; Dominguez, PS; Pulla, MP; Dominguez, AR; Casado, DI.
SEOM clinical guidelines for the treatment of diffuse large B-cell lymphoma.
CLINICAL & TRANSLATIONAL ONCOLOGY. 2010. 12(11): 764-760. 10.1007/s12094-010-0593-6. FIA: 1,254. Q4
Rodriguez-Abreu, D; Munoz, ML; Pulla, MP; Dominguez, AR; Casado, DI.
SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma.
CLINICAL & TRANSLATIONAL ONCOLOGY. 2010. 131(12): 446-441. 10.1007/s12094-010-0592-7. FIA: 1,254. Q4

2008

Sancho, JM; Morgades, M; Alonso, N; Deben, G; de Sevilla, AF; Vazqueze, L; Nicolas, C; Vela, JAG; Arranz, R; Abella, E; Canales, MA; Miralles, P; Sanchez, E; Hermosilla, M; Conde, E; Rueda, A; Ribera, JM.
Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin’s lymphoma in Spain.
MEDICINA CLINICA. 2008. 131(11): 405-401. 10.1157/13126952. FIA: 1,258. Q3
Sancho, JM; Morgades, M; Arranz, R; Fernandez-Abellan, P; Deben, G; Alonso, N; Blanes, M; Rodriguez, MJ; Nicolas, C; Sanchez, E; de Sevilla, AF; Conde, E; Ribera, JM.
Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
MEDICINA CLINICA. 2008. 26(1): 32-27. 10.1157/13126214. FIA: 1,258. Q3
Rueda, A; Sabin, P; Rifa, J; Llanos, M; Gomez-Codina, J; Lobo, F; Garcia, R; Herrero, J; Provencio, M; Jara, C.
R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.
HEMATOLOGICAL ONCOLOGY. 2008. 92(11): 1494-1489. 10.1002/hon.829. FIA: 2,333. Q3

2007

Gonzalez-Barca, E; Domingo-Domenech, E; Capote, FJ; Gomez-Codina, J; Salar, A; Bailen, A; Ribera, JM; Lopez, A; Briones, J; Munoz, A; Encuentra, M; de Sevilla, AF.
Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
HAEMATOLOGICA. 2007. (): -. 10.3324/haematol.11360. FIA: 5,516. Q1